Apellis Pharmaceuticals, Inc.
APLS
$23.27
-$0.22-0.94%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 54.30% | -153.69% | 36.72% | -52.55% | 43.31% |
| Total Depreciation and Amortization | 0.00% | -0.22% | -2.19% | 1.78% | 1.13% |
| Total Amortization of Deferred Charges | 3.89% | 0.68% | -10.79% | 176.47% | 213.16% |
| Total Other Non-Cash Items | -0.65% | 4.03% | -4.23% | -21.07% | -4.41% |
| Change in Net Operating Assets | 76.27% | -63.32% | -54.94% | 1,118.95% | 94.03% |
| Cash from Operations | 108.32% | -375.88% | -43.22% | 508.87% | 93.73% |
| Capital Expenditure | -512.50% | 60.00% | -- | 100.00% | 69.28% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -512.50% | 60.00% | -- | 100.00% | 69.28% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,233.81% | -82.87% | -35.84% | -50.42% | -45.61% |
| Repurchase of Common Stock | 100.00% | 53.33% | -7.14% | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -254.00% | 99.52% | -432.23% |
| Cash from Financing | 2,293.43% | 106.85% | -257.36% | -94.02% | -60.74% |
| Foreign Exchange rate Adjustments | 90.81% | 137.20% | -657.80% | -49.42% | 263.64% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 122.05% | -467.20% | -60.95% | 7.01% | 236.11% |